CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们此前已表明，使用肿瘤脉冲树突状细胞疫苗可增强卵巢癌中新抗原的识别。在此，一项纳入19例患者的1期临床研究（NCT01312376/UPCC26810）中，我们显示，随后过继转移经疫苗致敏、体外扩增的自体外周血T细胞可进一步重新激活此类反应。该治疗是安全的，并且在获得临床获益的患者中，细胞输注后观察到表位扩展及新的新肽反应性，提示肿瘤塑造免疫被重新激活。
We have previously shown that vaccination with tumor-pulsed dendritic cells amplifies neoantigen recognition in ovarian cancer.
Here, in a phase 1 clinical study ( NCT01312376 /UPCC26810) including 19 patients, we show that such responses are further reinvigorated by subsequent adoptive transfer of vaccine-primed, ex vivo-expanded autologous peripheral blood T cells. The treatment is safe, and epitope spreading with novel neopeptide reactivities was observed after cell infusion in patients who experienced clinical benefit, suggesting reinvigoration of tumor-sculpting immunity.
MEMBER ACCOUNT
登录成功会直接打开下一页。
